leadf
logo-loader
viewImugene Ltd

Imugene gets green light to start phase-1 clinical trial of new cancer immunotherapy PD-1 Vaxx

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene has completed all necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to begin human clinical trials.

Quick facts: Imugene Ltd

Price: 0.096 AUD

ASX:IMU
Market: ASX
Market Cap: $456.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene's Leslie Chong details dose escalation for its phase I clinical...

Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong discusses with Proactive's Andrew Scott the news the phase one clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, will proceed to the second dose. She says the cohort review committee agreed the therapy to be safe...

on 21/1/21

2 min read